Recombinant Plasma Protein Therapeutics Market

Recombinant Plasma Protein Therapeutics Market (Drug Class - Recombinant Coagulation Factors, Human C1 Esterase Inhibitor; Cell Line - Chinese Hamster Ovary (CHO) Cell Line, Baby Hamster Kidney (BHK) Cell Line, Human Embryonic Kidney (HEK) Cell Line, and Others; Indication - Hemophilia A, Hemophilia B, Von Willebrand Disease) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 - 2026

Global Recombinant Plasma Protein Therapeutics Market - Snapshot

The global recombinant plasma protein therapeutics market is driven by various factors such as shift from use of plasma-derived proteins to recombinant therapies, rise in awareness about rare disease management and increased focus on investments in rare diseases. Additionally, steady increase in the number of patients with rare hematological diseases and product approvals by regulatory authorities such as the Food and Drug Administration (FDA), European Commission, and Ministry of Health, Labour and Welfare (Japan) are anticipated to drive the market significantly during the forecast period. However, the high cost of treatment and availability of alternative therapies are likely to restrain the global market.

recombinant plasma protein

The global recombinant plasma protein therapeutics market has been segmented based on drug class, cell line, and indication. Based on drug class, the market has been classified into recombinant coagulation factors and human C1 esterase inhibitor. The recombinant coagulation factors segment has been further sub-segmented into recombinant coagulation factor VIII, recombinant coagulation factor IX, recombinant coagulation factor VIIa, and others. The recombinant coagulation factor VIII sub-segment is projected to account for a major share of the recombinant coagulation factors segment of the market by 2026, due to the increase in number of hemophilia A cases across the globe, new product launches, and use of recombinant plasma protein therapies for the treatment of hemophilia A. The recombinant coagulation factor VIIa sub-segment is anticipated to expand at a steady pace during the forecast period. In terms of cell line, the market has been categorized into Chinese hamster ovary (CHO) cell line, baby hamster kidney (BHK) cell line, human embryonic kidney (HEK) cell line, and others. The Chinese hamster ovary (CHO) cell line segment is expected to expand at a prominent CAGR due to an increase in the utilization of CHO cell lines for manufacturing therapeutic products. Based on indication, the market has been segregated into hemophilia A, hemophilia B, Von Willebrand disease, and others 

Based on region, the global recombinant plasma protein therapeutics market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is anticipated to hold a prominent share of the global market. In North America, the market in the U.S. is anticipated to expand at a rapid pace, due to a surge in the demand for recombinant coagulation factor VII and IX, rise in the emphasis on the management of rare diseases such as hemophilia A, hemophilia B, and Von Willebrand disease, and increase in the number of market players offering recombinant plasma proteins. Additionally, market players are focused on increasing global presence through distribution agreements, partnerships, and geographical expansion. 

In Europe, increasing number of established biotechnology & pharmaceutical companies and research institutes, universities, and commercial players are obtaining funds for research & development studies in the field of recombinant DNA technology, which in turn is projected to boost the market. Furthermore, advancements in genetic engineering and biotechnology in countries such as Germany, U.K., and France significantly drive the opportunities of developing new therapeutics products for diseases. Moreover, in January 2017, CSL Limited received approval and marketing authorization from European Commission for AFSTYLA, indicated for the treatment of Hemophilia A. Such approvals increased the availability of drugs in Europe. 

Major players operating in the global recombinant plasma protein therapeutics market include CSL Limited, Shire (Takeda Pharmaceutical Company Limited), Octapharma, Novo Nordisk A/S, Bayer AG, Bioverativ Therapeutics, Inc. (Sanofi), Aptevo Therapeutics, Pharming Group NV, and Pfizer Inc.  

Expanding Cases of Hemophilia among many Individuals to Bring Profitable Growth for the Recombinant Plasma Protein Therapeutics Market

The recombinant plasma protein therapeutics market will gain considerable growth opportunities during the forecast period of 2018-2026 owing to an increase in the demand for advanced therapies across a large chunk of the global populace. Technological advancements and an increase in research and development activities coupled with the rising geriatric population are some major factors that will influence the growth to a considerable extent.

  • Plasma proteins are prominently utilized in replacement therapies. These therapies are used for treating rare conditions such as hemophilia and other bleeding disorders. The expanding number of rare hematology cases will bring promising growth.
  • Diverse awareness campaigns organized by various government and non-government organizations about hemophilia A and hemophilia B will bring tremendous growth opportunities for the recombinant plasma protein therapeutics market Furthermore, quick approvals from regulatory authorities are also helping the recombinant plasma protein therapeutics market to gain good growth opportunities. These factors bode well for the growth.
  • Rising investment in research and development activities from the players in the recombinant plasma protein therapeutics market will serve as a vital growth-generating aspect. The players invest in these activities for formulating new developments and strategies that help in increasing the demand for recombinant plasma protein therapeutics.  These activities eventually help in sowing the seeds of growth.
  • The players also indulge in strategic collaborations. The collaborations strengthen the position of manufacturers in the recombinant plasma protein therapeutics market, which ultimately results in an increase in the growth rate.
  • The COVID-19 pandemic will not have much impact on the growth of the recombinant plasma protein therapeutics market as it comes under healthcare services and is exempt from all sorts of lockdown restrictions. The lockdown restrictions imposed by numerous countries at the start of the pandemic in 2020 had a minimal negative effect on the recombinant plasma protein therapeutics market.

The global recombinant plasma protein therapeutics market has been segmented as below:

Drug Class

  • Recombinant Coagulation Factors
    • Recombinant Coagulation Factor VIII
    • Recombinant Coagulation Factor IX
    • Recombinant Coagulation Factor VIIa
    • Others
  • Human C1 Esterase Inhibitor

Cell Line

  • Chinese Hamster Ovary (CHO) Cell Line
  • Baby Hamster Kidney (BHK) Cell Line
  • Human Embryonic Kidney (HEK) Cell Line
  • Others

Indication

  • Hemophilia A
  • Hemophilia B
  • Von Willebrand Disease
  • Others

Region

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • U.K.
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • India
    • China
    • Japan
    • Australia & New Zealand
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC Countries
    • South Africa
    • Rest of Middle East & Africa

    1. Preface
         1.1. Market Definition and Scope
         1.2. Market Segmentation
         1.3. Key Research Objectives
         1.4. Research Highlights

    2. Assumptions and Research Methodology

    3. Executive Summary : Global Recombinant Plasma Protein Therapeutics Market

    4. Market Overview
         4.1. Introduction
                4.1.1. Product Definition
                4.1.2. Industry Evolution / Developments
         4.2. Overview
         4.3. Market Dynamics
                4.3.1. Drivers
                              4.3.1.1 Shift from use of Plasma Derived Proteins to Recombinant Therapies
                              4.3.1.2 Rising Awareness about Rare Disease Management
                              4.3.1.3 Increasing Focus on Investments in Rare Disease
                4.3.2. Restraints
                              4.3.2.1 High Cost of Treatment
                              4.3.2.2 Availability of Alternative Therapies
                4.3.3. Opportunities
                              4.3.3.1 Growth Opportunities in Developing Markets
                              4.3.3.2 Strategic Approaches such as Partnership and Distribution Agreements
         4.4. Global Recombinant Plasma Protein Therapeutics Market Analysis and Forecast, 2016–2026

    5. Key Insights
         5.1. New Product Launch and Regulatory Approvals
         5.2. Key Mergers & Acquisitions 
         5.3. Regulatory Scenario by Region/Country

    6. Global Recombinant Plasma Protein Therapeutics Market Analysis and Forecast, by Drug Class 
         6.1. Introduction & Definition
         6.2. Key Findings / Developments
         6.3. Global Recombinant Plasma Protein Therapeutics Market Value Forecast, by Drug Class, 2016–2026
                6.3.1. Recombinant Coagulation Factors
                              6.3.1.1. Recombinant Coagulation Factor VIII
                              6.3.1.2. Recombinant Coagulation Factor IX
                              6.3.1.3. Recombinant Coagulation Factor VIIa
                              6.3.1.4. Others
                6.3.2. Human C1 Esterase Inhibitor
         6.4. Global Recombinant Plasma Protein Therapeutics Market Attractiveness, by Drug Class 

    7. Global Recombinant Plasma Protein Therapeutics Market Analysis and Forecast, by Cell Line 
         7.1. Introduction & Definition
         7.2. Key Findings / Developments
         7.3. Global Recombinant Plasma Protein Therapeutics Market Value Forecast, by Cell Line, 2016–2026
                7.3.1. Chinese Hamster Ovary (CHO) Cell Line
                7.3.2. Baby Hamster Kidney (BHK) Cell Line
                7.3.3. Human Embryonic Kidney (HEK) Cell Line
                7.3.4. Others
         7.4. Global Recombinant Plasma Protein Therapeutics Market Attractiveness, by Cell Line 

    8. Global Recombinant Plasma Protein Therapeutics Market Analysis and Forecast, by Indication 
         8.1. Introduction & Definition
         8.2. Key Findings / Developments
         8.3. Global Recombinant Plasma Protein Therapeutics Market Value Forecast, by Indication, 2016–2026
                8.3.1. Hemophilia A
                8.3.2. Hemophilia B
                8.3.3. Von Willebrand Disease
                8.3.4. Others
         8.4. Global Recombinant Plasma Protein Therapeutics Market Attractiveness, by Indication 

    9. Global Recombinant Plasma Protein Therapeutics Market Analysis and Forecast, by Region
         9.1. Key Findings
         9.2. Global Recombinant Plasma Protein Therapeutics Market Value Forecast, by Region
                9.2.1. North America 
                9.2.2. Europe 
                9.2.3. Asia Pacific 
                9.2.4. Latin America 
                9.2.5. Middle East & Africa 
         9.3. Global Recombinant Plasma Protein Therapeutics Market Attractiveness, by Region

    10. North America Recombinant Plasma Protein Therapeutics Market Analysis and Forecast
         10.1. Introduction
                10.1.1. Key Findings
         10.2. North America Recombinant Plasma Protein Therapeutics Market Value Forecast, by Drug Class, 2016–2026
                10.2.1. Recombinant Coagulation Factors
                          10.2.1.1. Recombinant Coagulation Factor VIII
                          10.2.1.2. Recombinant Coagulation Factor IX
                          10.2.1.3. Recombinant Coagulation Factor VIIa
                          10.2.1.4. Others
                10.2.2. Human C1 Esterase Inhibitor
         10.3. North America Recombinant Plasma Protein Therapeutics Market Value Forecast, by Cell Line, 2016–2026
                10.3.1. Chinese Hamster Ovary (CHO) Cell Line
                10.3.2. Baby Hamster Kidney (BHK) Cell Line
                10.3.3. Human Embryonic Kidney (HEK) Cell Line
                10.3.4. Others
         10.4. North America Recombinant Plasma Protein Therapeutics Market Value Forecast, by Indication, 2016–2026
                10.4.1. Hemophilia A
                10.4.2. Hemophilia B
                10.4.3. Von Willebrand Disease
                10.4.4. Others
         10.5. North America Recombinant Plasma Protein Therapeutics Market Value Forecast, by Country, 2016–2026
                10.5.1. U.S.
                10.5.2. Canada
         10.6. North America Recombinant Plasma Protein Therapeutics Market Attractiveness Analysis 
                10.6.1. By Drug Class 
                10.6.2. By Cell Line 
                10.6.3. By Indication 
                10.6.4. By Country

    11. Europe Recombinant Plasma Protein Therapeutics Market Analysis and Forecast
         11.1. Introduction
                11.1.1. Key Findings
         11.2. Europe Recombinant Plasma Protein Therapeutics Market Value Forecast, by Drug Class, 2016–2026
                11.2.1. Recombinant Coagulation Factors
                          11.2.1.1. Recombinant Coagulation Factor VIII
                          11.2.1.2. Recombinant Coagulation Factor IX
                          11.2.1.3. Recombinant Coagulation Factor VIIa
                          11.2.1.4. Others
                11.2.2. Human C1 Esterase Inhibitor
         11.3. Europe Recombinant Plasma Protein Therapeutics Market Value Forecast, by Cell Line, 2016–2026
                11.3.1. Chinese Hamster Ovary (CHO) Cell Line
                11.3.2. Baby Hamster Kidney (BHK) Cell Line
                11.3.3. Human Embryonic Kidney (HEK) Cell Line
                11.3.4. Others
         11.4. Europe Recombinant Plasma Protein Therapeutics Market Value Forecast, by Indication, 2016–2026
                11.4.1. Hemophilia A
                11.4.2. Hemophilia B
                11.4.3. Von Willebrand Disease
                11.4.4. Others
         11.5. Europe Recombinant Plasma Protein Therapeutics Market Value Forecast, by Country/Sub-region, 2016–2026
                11.5.1. Germany
                11.5.2. U.K.
                11.5.3. France
                11.5.4. Spain
                11.5.5. Italy
                11.5.6. Rest of Europe
         11.6. Europe Recombinant Plasma Protein Therapeutics Market Attractiveness Analysis 
                11.6.1. By Drug Class 
                11.6.2. By Cell Line 
                11.6.3. By Indication 
                11.6.4. By Country/Sub-region

    12. Asia Pacific Recombinant Plasma Protein Therapeutics Market Analysis and Forecast
         12.1. Introduction
                12.1.1. Key Findings
         12.2. Asia Pacific Recombinant Plasma Protein Therapeutics Market Value Forecast, by Drug Class, 2016–2026
                12.2.1. Recombinant Coagulation Factors
                          12.2.1.1. Recombinant Coagulation Factor VIII
                          12.2.1.2. Recombinant Coagulation Factor IX
                          12.2.1.3. Recombinant Coagulation Factor VIIa
                          12.2.1.4. Others
                12.2.2. Human C1 Esterase Inhibitor
         12.3. Asia Pacific Recombinant Plasma Protein Therapeutics Market Value Forecast, by Cell Line, 2016–2026
                12.3.1. Chinese Hamster Ovary (CHO) Cell Line
                12.3.2. Baby Hamster Kidney (BHK) Cell Line
                12.3.3. Human Embryonic Kidney (HEK) Cell Line
                12.3.4. Others
         12.4. Asia Pacific Recombinant Plasma Protein Therapeutics Market Value Forecast, by Indication, 2016–2026
                12.4.1. Hemophilia A
                12.4.2. Hemophilia B
                12.4.3. Von Willebrand Disease
                12.4.4. Others
         12.5. Asia Pacific Recombinant Plasma Protein Therapeutics Market Value Forecast, by Country/Sub-region, 2016–2026
                12.5.1. China
                12.5.2. Japan
                12.5.3. India
                12.5.4. Australia & New Zealand
                12.5.5. Rest of Asia Pacific
         12.6. Asia Pacific Recombinant Plasma Protein Therapeutics Market Attractiveness Analysis 
                12.6.1. By Drug Class 
                12.6.2. By Cell Line 
                12.6.3. By Indication 
                12.6.4. By Country/Sub-region

    13. Latin America Recombinant Plasma Protein Therapeutics Market Analysis and Forecast
         13.1. Introduction
                13.1.1. Key Findings
         13.2. Latin America Recombinant Plasma Protein Therapeutics Market Value Forecast, by Drug Class, 2016–2026
                13.2.1. Recombinant Coagulation Factors
                          13.2.1.1. Recombinant Coagulation Factor VIII
                          13.2.1.2. Recombinant Coagulation Factor IX
                          13.2.1.3. Recombinant Coagulation Factor VIIa
                          13.2.1.4. Others
                13.2.2. Human C1 Esterase Inhibitor
         13.3. Latin America Recombinant Plasma Protein Therapeutics Market Value Forecast, by Cell Line, 2016–2026
                13.3.1. Chinese Hamster Ovary (CHO) Cell Line
                13.3.2. Baby Hamster Kidney (BHK) Cell Line
                13.3.3. Human Embryonic Kidney (HEK) Cell Line
                13.3.4. Others
         13.4. Latin America Recombinant Plasma Protein Therapeutics Market Value Forecast, by Indication, 2016–2026
                13.4.1. Hemophilia A
                13.4.2. Hemophilia B
                13.4.3. Von Willebrand Disease
                13.4.4. Others
         13.5. Latin America Recombinant Plasma Protein Therapeutics Market Value Forecast, by Country/Sub-region, 2016–2026
                13.5.1. Brazil
                13.5.2. Mexico
                13.5.3. Rest of Latin America
         13.6. Latin America Recombinant Plasma Protein Therapeutics Market Attractiveness Analysis 
                13.6.1. By Drug Class 
                13.6.2. By Cell Line 
                13.6.3. By Indication 
                13.6.4. By Country/Sub-region

    14. Middle East & Africa Recombinant Plasma Protein Therapeutics Market Analysis and Forecast
         14.1. Introduction
                14.1.1. Key Findings
         14.2. Middle East & Africa Recombinant Plasma Protein Therapeutics Market Value Forecast, by Drug Class, 2016–2026
                14.2.1. Recombinant Coagulation Factors
                          14.2.1.1. Recombinant Coagulation Factor VIII
                          14.2.1.2. Recombinant Coagulation Factor IX
                          14.2.1.3. Recombinant Coagulation Factor VIIa
                          14.2.1.4. Others
                14.2.2. Human C1 Esterase Inhibitor
         14.3. Middle East & Africa Recombinant Plasma Protein Therapeutics Market Value Forecast, by Cell Line, 2016–2026
                14.3.1. Chinese Hamster Ovary (CHO) Cell Line
                14.3.2. Baby Hamster Kidney (BHK) Cell Line
                14.3.3. Human Embryonic Kidney (HEK) Cell Line
                14.3.4. Others
         14.4. Middle East & Africa Recombinant Plasma Protein Therapeutics Market Value Forecast, by Indication, 2016–2026
                14.4.1. Hemophilia A
                14.4.2. Hemophilia B
                14.4.3. Von Willebrand Disease
                14.4.4. Others
         14.5. Middle East & Africa Recombinant Plasma Protein Therapeutics Market Value Forecast, by Country/Sub-region, 2016–2026
                14.5.1. GCC Countries
                14.5.2. South Africa
                14.5.3. Rest of Middle East & Africa
         14.6. Middle East & Africa Recombinant Plasma Protein Therapeutics Market Attractiveness Analysis 
                14.6.1. By Drug Class 
                14.6.2. By Cell Line 
                14.6.3. By Indication 
                14.6.4. By Country/Sub-region

    15. Competitive Landscape
         15.1. Market Player – Competition Matrix (By Tier and Size of companies)
         15.2. Market Share Analysis By Company (2016)
         15.3. Company Profiles
                15.3.1. CSL Limited
                          15.3.1.1. Company Details
                          15.3.1.2. Products Portfolio
                          15.3.1.3. Financial Overview
                          15.3.1.4. Strategic Overview
                          15.3.1.5. SWOT Analysis
                15.3.2. Shire (Takeda Pharmaceutical Company Limited)
                          15.3.2.1. Company Details
                          15.3.2.2. Products Portfolio
                          15.3.2.3. Financial Overview
                          15.3.2.4. Strategic Overview
                          15.3.2.5. SWOT Analysis
                15.3.3. Octapharma
                          15.3.3.1. Company Details
                          15.3.3.2. Products Portfolio
                          15.3.3.3. Financial Overview
                          15.3.3.4. Strategic Overview
                          15.3.3.5. SWOT Analysis
                15.3.4. Novo Nordisk A/S
                          15.3.4.1. Company Details
                          15.3.4.2. Products Portfolio
                          15.3.4.3. Financial Overview
                          15.3.4.4. Strategic Overview
                          15.3.4.5. SWOT Analysis
                15.3.5. Bayer AG
                          15.3.5.1. Company Details
                          15.3.5.2. Products Portfolio
                          15.3.5.3. Financial Overview
                          15.3.5.4. Strategic Overview
                          15.3.5.5. SWOT Analysis
                15.3.6. Pfizer Inc.
                          15.3.6.1. Company Details
                          15.3.6.2. Products Portfolio
                          15.3.6.3. Financial Overview
                          15.3.6.4. Strategic Overview
                          15.3.6.5. SWOT Analysis
                15.3.7. Bioverativ Therapeutics, Inc. (Sanofi)
                          15.3.7.1. Company Details
                          15.3.7.2. Products Portfolio
                          15.3.7.3. Financial Overview
                          15.3.7.4. Strategic Overview
                          15.3.7.5. SWOT Analysis
                15.3.8. Aptevo Therapeutics
                          15.3.8.1. Company Details
                          15.3.8.2. Products Portfolio
                          15.3.8.3. Financial Overview
                          15.3.8.4. Strategic Overview
                          15.3.8.5. SWOT Analysis
                15.3.9. Pharming Group NV
                          15.3.9.1. Company Details
                          15.3.9.2. Products Portfolio
                          15.3.9.3. Financial Overview
                          15.3.9.4. Strategic Overview
                          15.3.9.5. SWOT Analysis

    List of Tables

    Table 01 Global Recombinant Plasma Protein Therapeutics Market, New Product Launch and Regulatory Approvals, 2017?2018
    Table 02 Global Recombinant Plasma Protein Therapeutics Market, New Product Launch and Regulatory Approvals, 2015?2017 
    Table 03 Global Recombinant Plasma Protein Therapeutics Market, New Product Launch and Regulatory Approvals, 2014?2015 
    Table 04 Global Recombinant Plasma Protein Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2016–2026
    Table 05 Global Recombinant Plasma Protein Therapeutics Market Value (US$ Mn) Forecast, by Recombinant Coagulation Factors, 2016–2026
    Table 06 Global Recombinant Plasma Protein Therapeutics Market Value (US$ Mn) Forecast, by Cell Line, 2016–2026
    Table 07 Global Recombinant Plasma Protein Therapeutics Market Value (US$ Mn) Forecast, by Indication, 2016–2026
    Table 08 Global Recombinant Plasma Protein Therapeutics Market Value (US$ Mn) Forecast, by Region, 2016–2026
    Table 09 North America Recombinant Plasma Protein Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2016–2026
    Table 10 North America Recombinant Plasma Protein Therapeutics Market Value (US$ Mn) Forecast, by Recombinant Coagulation Factors, 2016–2026
    Table 11 North America Recombinant Plasma Protein Therapeutics Market Value (US$ Mn) Forecast, by Cell Line, 2016–2026
    Table 12 North America Recombinant Plasma Protein Therapeutics Market Value (US$ Mn) Forecast, by Indication, 2016–2026
    Table 13 North America Recombinant Plasma Protein Therapeutics Market Value (US$ Mn) Forecast, by Country, 2016–2026
    Table 14 Europe Recombinant Plasma Protein Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2016–2026
    Table 15 Europe Recombinant Plasma Protein Therapeutics Market Value (US$ Mn) Forecast, by Recombinant Coagulation Factors, 2016–2026
    Table 16 Europe Recombinant Plasma Protein Therapeutics Market Value (US$ Mn) Forecast, by Cell Line, 2016–2026
    Table 17 Europe Recombinant Plasma Protein Therapeutics Market Value (US$ Mn) Forecast, by Indication, 2016–2026
    Table 18 Europe Recombinant Plasma Protein Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
    Table 19 Asia Pacific Recombinant Plasma Protein Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2016–2026
    Table 20 Asia Pacific Recombinant Plasma Protein Therapeutics Market Value (US$ Mn) Forecast, by Recombinant Coagulation Factors, 2016–2026
    Table 21 Asia Pacific Recombinant Plasma Protein Therapeutics Market Value (US$ Mn) Forecast, by Cell Line, 2016–2026
    Table 22 Asia Pacific Recombinant Plasma Protein Therapeutics Market Value (US$ Mn) Forecast, by Indication, 2016–2026
    Table 23 Asia Pacific Recombinant Plasma Protein Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
    Table 24 Latin America Recombinant Plasma Protein Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2016–2026
    Table 25 Latin America Recombinant Plasma Protein Therapeutics Market Value (US$ Mn) Forecast, by Recombinant Coagulation Factors, 2016–2026
    Table 26 Latin America Recombinant Plasma Protein Therapeutics Market Value (US$ Mn) Forecast, by Cell Line, 2016–2026
    Table 27 Latin America Recombinant Plasma Protein Therapeutics Market Value (US$ Mn) Forecast, by Indication, 2016–2026
    Table 28 Latin America Recombinant Plasma Protein Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
    Table 29 Middle East & Africa Recombinant Plasma Protein Therapeutics Market Value (US$ Mn) Forecast, by Drug Class, 2016–2026
    Table 30 Middle East & Africa Recombinant Plasma Protein Therapeutics Market Value (US$ Mn) Forecast, by Recombinant Coagulation Factors, 2016–2026
    Table 31 Middle East & Africa Recombinant Plasma Protein Therapeutics Market Value (US$ Mn) Forecast, by Cell Line, 2016–2026
    Table 32 Middle East & Africa Recombinant Plasma Protein Therapeutics Market Value (US$ Mn) Forecast, by Indication, 2016–2026
    Table 33 Middle East & Africa Recombinant Plasma Protein Therapeutics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026

    List of Figures

    Figure 01 Global Recombinant Plasma Protein Therapeutics Market Value (US$ Mn) and Distribution, by Region, 2017 and 2026
    Figure 02 Global Recombinant Plasma Protein Therapeutics Market Value (US$ Mn), by Drug Class, 2017
    Figure 03 Global Recombinant Plasma Protein Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2016–2026
    Figure 04 Global Recombinant Plasma Protein Therapeutics Market Value Share Analysis, by Drug Class, 2017 and 2026
    Figure 05 Global Recombinant Plasma Protein Therapeutics Market Value (US$ Mn) & Y-o-Y Growth (%), by Recombinant Coagulation Factors, 2016–2026
    Figure 06 Global Recombinant Plasma Protein Therapeutics Market Value (US$ Mn) & Y-o-Y Growth (%), by Human C1 Esterase Inhibitor, 2016–2026
    Figure 07 Global Recombinant Plasma Protein Therapeutics Market Attractiveness Analysis, by Drug Class, 2018–2026
    Figure 08 Global Recombinant Plasma Protein Therapeutics Market Value Share Analysis, by Cell Line, 2017 and 2026
    Figure 09 Global Recombinant Plasma Protein Therapeutics Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, by Chinese Hamster Ovary (CHO) Cell Line , 2016–2026
    Figure 10 Global Recombinant Plasma Protein Therapeutics Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, by Baby Hamster Kidney (BHK) Cell Line, 2016–2026
    Figure 11 Global Recombinant Plasma Protein Therapeutics Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, by Human Embryonic Kidney (HEK) Cell Line, 2016–2026
    Figure 12 Global Recombinant Plasma Protein Therapeutics Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, by Others, 2016–2026
    Figure 13 Global Recombinant Plasma Protein Therapeutics Market Attractiveness Analysis, by Cell Line, 2018–2026
    Figure 14 Global Recombinant Plasma Protein Therapeutics Market Value Share Analysis, by Indication, 2017 and 2026
    Figure 15 Global Recombinant Plasma Protein Therapeutics Market Value (US$ Mn) & Y-o-Y Growth (%), by Hemophilia A, 2016–2026
    Figure 16 Global Recombinant Plasma Protein Therapeutics Market Value (US$ Mn) & Y-o-Y Growth (%), by Hemophilia B, 2016–2026
    Figure 17 Global Recombinant Plasma Protein Therapeutics Market Value (US$ Mn) & Y-o-Y Growth (%), by Von Willebrand Disease, 2016–2026
    Figure 18 Global Recombinant Plasma Protein Therapeutics Market Value (US$ Mn) & Y-o-Y Growth (%), by Others, 2016–2026
    Figure 19 Global Recombinant Plasma Protein Therapeutics Market Attractiveness Analysis, by Indication, 2018–2026
    Figure 20 Global Recombinant Plasma Protein Therapeutics Market Value Share Analysis, by Region, 2017 and 2026
    Figure 21 Global Recombinant Plasma Protein Therapeutics Market Attractiveness Analysis, by Region, 2018–2026
    Figure 22 North America Recombinant Plasma Protein Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2016–2026
    Figure 23 North America Recombinant Plasma Protein Therapeutics Market Value Share Analysis, by Drug Class, 2017 and 2026
    Figure 24 North America Recombinant Plasma Protein Therapeutics Market Attractiveness Analysis, by Drug Class, 2018–2026
    Figure 25 North America Recombinant Plasma Protein Therapeutics Market Value Share Analysis, by Cell Line, 2017 and 2026
    Figure 26 North America Recombinant Plasma Protein Therapeutics Market Attractiveness Analysis, by Cell Line, 2018–2026
    Figure 27 North America Recombinant Plasma Protein Therapeutics Market Value Share Analysis, by Indication, 2017 and 2026
    Figure 28 North America Recombinant Plasma Protein Therapeutics Market Attractiveness Analysis, by Indication, 2018–2026
    Figure 29 North America Recombinant Plasma Protein Therapeutics Market Value Share Analysis, by Country, 2017 and 2026
    Figure 30 North America Recombinant Plasma Protein Therapeutics Market Attractiveness Analysis, by Country, 2018–2026
    Figure 31 Europe Recombinant Plasma Protein Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2016–2026
    Figure 32 Europe Recombinant Plasma Protein Therapeutics Market Value Share Analysis, by Drug Class, 2017 and 2026
    Figure 33 Europe Recombinant Plasma Protein Therapeutics Market Attractiveness Analysis, by Drug Class, 2018–2026
    Figure 34 Europe Recombinant Plasma Protein Therapeutics Market Value Share Analysis, by Cell Line, 2017 and 2026
    Figure 35 Europe Recombinant Plasma Protein Therapeutics Market Attractiveness Analysis, by Cell Line, 2018–2026
    Figure 36 Europe Recombinant Plasma Protein Therapeutics Market Value Share Analysis, by Indication, 2017 and 2026
    Figure 37 Europe Recombinant Plasma Protein Therapeutics Market Attractiveness Analysis, by Indication, 2018–2026
    Figure 38 Europe Recombinant Plasma Protein Therapeutics Market Value Share Analysis, by Country/Sub-region, 2017 and 2026
    Figure 39 Europe Recombinant Plasma Protein Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2018–2026
    Figure 40 Asia Pacific Recombinant Plasma Protein Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2016–2026
    Figure 41 Asia Pacific Recombinant Plasma Protein Therapeutics Market Value Share Analysis, by Drug Class, 2017 and 2026
    Figure 42 Asia Pacific Recombinant Plasma Protein Therapeutics Market Attractiveness Analysis, by Drug Class, 2018–2026
    Figure 43 Asia Pacific Recombinant Plasma Protein Therapeutics Market Value Share Analysis, by Cell Line, 2017 and 2026
    Figure 44 Asia Pacific Recombinant Plasma Protein Therapeutics Market Attractiveness Analysis, by Cell Line, 2018–2026
    Figure 45 Asia Pacific Recombinant Plasma Protein Therapeutics Market Value Share Analysis, by Indication, 2017 and 2026
    Figure 46 Asia Pacific Recombinant Plasma Protein Therapeutics Market Attractiveness Analysis, by Indication, 2018–2026
    Figure 47 Asia Pacific Recombinant Plasma Protein Therapeutics Market Value Share Analysis, by Country/Sub-region, 2017 and 2026
    Figure 48 Asia Pacific Recombinant Plasma Protein Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2018–2026
    Figure 49 Latin America Recombinant Plasma Protein Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2016–2026
    Figure 50 Latin America Recombinant Plasma Protein Therapeutics Market Value Share Analysis, by Drug Class, 2017 and 2026
    Figure 51 Latin America Recombinant Plasma Protein Therapeutics Market Attractiveness Analysis, by Drug Class, 2018–2026
    Figure 52 Latin America Recombinant Plasma Protein Therapeutics Market Value Share Analysis, by Cell Line, 2017 and 2026
    Figure 53 Latin America Recombinant Plasma Protein Therapeutics Market Attractiveness Analysis, by Cell Line, 2018–2026
    Figure 54 Latin America Recombinant Plasma Protein Therapeutics Market Value Share Analysis, by Indication, 2017 and 2026
    Figure 55 Latin America Recombinant Plasma Protein Therapeutics Market Attractiveness Analysis, by Indication, 2018–2026
    Figure 56 Latin America Recombinant Plasma Protein Therapeutics Market Value Share Analysis, by Country/Sub-region, 2017 and 2026
    Figure 57 Latin America Recombinant Plasma Protein Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2018–2026
    Figure 58 Middle East & Africa Recombinant Plasma Protein Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2016–2026
    Figure 59 Middle East & Africa Recombinant Plasma Protein Therapeutics Market Value Share Analysis, by Drug Class, 2017 and 2026
    Figure 60 Middle East & Africa Recombinant Plasma Protein Therapeutics Market Attractiveness Analysis, by Drug Class, 2018–2026
    Figure 61 Middle East & Africa Recombinant Plasma Protein Therapeutics Market Value Share Analysis, by Cell Line, 2017 and 2026
    Figure 62 Middle East & Africa Recombinant Plasma Protein Therapeutics Market Attractiveness Analysis, by Cell Line, 2018–2026
    Figure 63 Middle East & Africa Recombinant Plasma Protein Therapeutics Market Value Share Analysis, by Indication, 2017 and 2026
    Figure 64 Middle East & Africa Recombinant Plasma Protein Therapeutics Market Attractiveness Analysis, by Indication, 2018–2026
    Figure 65 Middle East & Africa Recombinant Plasma Protein Therapeutics Market Value Share Analysis, by Country/Sub-region, 2017 and 2026
    Figure 66 Middle East & Africa Recombinant Plasma Protein Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2018–2026
    Figure 67 Global Recombinant Plasma Protein Therapeutics Market Share, by Company, 2017
    Figure 68 CSL Behring Business Segment Revenue (US$ Mn) and Y-o-Y Growth (%), 2016–2018
    Figure 69 CSL Limited R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2016–2018
    Figure 70 CSL Limited Breakdown of Net Sales (%), by Region, 2018
    Figure 71 CSL Behring Breakdown of Net Sales (%), by Therapeutic Area, 2018
    Figure 72 Shire Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2017
    Figure 73 Shire R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2015–2017
    Figure 74 Shire Breakdown of Net Sales (% Share), by Region (2017)
    Figure 75 Shire Breakdown of Net Sales (% Share), by Therapeutic Areas (2017)
    Figure 76 Octapharma Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2017
    Figure 77 Octapharma Research and Development Expenses, 2015-2017
    Figure 78 Novo Nordisk A/S Biopharmaceuticals Business Segment Revenue (US$ Mn) and Y-o-Y Growth (%), 2017–2018
    Figure 79 Novo Nordisk A/S R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2016–2018
    Figure 80 Novo Nordisk A/S Breakdown of Net Sales (%), by Region, 2018
    Figure 81 Novo Nordisk A/S Biopharmaceuticals Business Segment Breakdown of Net Sales (%), by Therapeutic Area, 2018
    Figure 82 Bayer AG Revenue (US$ Mn) and Y-o-Y Growth (%), 2016–2017
    Figure 83 Bayer AG Pharmaceutical Business Segment R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2015–2017
    Figure 84 Bayer AG Breakdown of Net Sales (%), by Region, 2017
    Figure 85 Bayer AG Breakdown of Net Sales (%), by Business Segment, 2017
    Figure 86 Pfizer Inc. Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2017
    Figure 87 Pfizer Inc. R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2015–2017
    Figure 88 Pfizer Inc. Breakdown of Net Sales (%), by Region, 2017
    Figure 89 Pfizer Inc. Breakdown of Net Sales (%), by Business Segment, 2017
    Figure 90 Bioverativ Therapeutics, Inc. Pharmaceuticals Segment Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2017
    Figure 91 Bioverativ Therapeutics, Inc. R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2014–2017
    Figure 92 Bioverativ Therapeutics, Inc. Breakdown of Net Sales (%), by Country, 2017
    Figure 93 Aptevo Therapeutics Revenue (US$ Mn) and Y-o-Y Growth (%), 2016–2017
    Figure 94 Aptevo Therapeutics IXINITY R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2015-2017
    Figure 95 Pharming Group NV Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2017
    Figure 96 Pharming Group NV R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2015–2017
    Figure 97 Pharming Group NV Breakdown of Net Sales (%), by Region, 2017

Copyright © Transparency Market Research, Inc. All Rights reserved